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Diagnosis of hepatic steatosis by contrast-enhanced abdominal
computed tomography*
Diagnóstico da esteatose hepática pela tomografia computadorizada de abdome com meio de contraste
intravenoso
Rodrigo da Fonseca Monjardim1, Danilo Manuel Cerqueira Costa1, Ricardo Francisco Tavares
Romano1, Priscila Silveira Salvadori1, Jaime de Vargas Conde dos Santos1, Augusto Castelli
Von Atzingen2, David Carlos Shigueoka3, Giuseppe D’Ippolito3
Objective: To evaluate the diagnostic capacity of abdominal computed tomography in the assessment of hepatic steatosis
using the portal phase with a simplified calculation method as compared with the non-contrast-enhanced phase. Materials
and Methods: In the present study, 150 patients were retrospectively evaluated by means of non-contrast-enhanced
and contrast-enhanced computed tomography. One hundred patients had hepatic steatosis and 50 were control subjects.
For the diagnosis of hepatic steatosis in the portal phase, the authors considered a result of < 104 HU calculated by the
formula [L – 0.3 × (0.75 × P + 0.25 × A)] / 0.7, where L, P and A represent the attenuation of the liver, of the main
portal vein and abdominal aorta, respectively. Sensitivity, specificity, positive and negative predictive values were calculated,
using non-contrast-enhanced computed tomography as the reference standard. Results: The simplified calculation method
with portal phase for the diagnosis of hepatic steatosis showed 100% sensitivity, 36% specificity, negative predictive
value of 100% and positive predictive value of 75.8%. The rate of false positive results was 64%. False negative results
were not observed. Conclusion: The portal phase presents an excellent sensitivity in the diagnosis of hepatic steatosis,
as compared with the non-contrast-enhanced phase of abdominal computed tomography. However, the method has low
specificity.
Keywords: Fatty liver; Steatosis; Liver disease; Tomography; Multidetector computed tomography; Contrast media.
Objetivo: Comparar a capacidade diagnóstica para esteatose hepática utilizando-se a fase portal com método simpli-
ficado de cálculo com a fase sem contraste na tomografia computadorizada de abdome. Materiais e Métodos: Foi
realizado estudo retrospectivo em 150 pacientes submetidos a tomografia computadorizada de abdome sem e com
contraste intravenoso, 100 deles com esteatose hepática e 50 controles. Para diagnóstico de esteatose hepática na fase
portal considerou-se um resultado < 104 UH aplicando-se a fórmula [L – 0,3 × (0,75 × P + 0,25 × A)] / 0,7, onde L, P
e A representam a atenuação hepática, da veia porta e da aorta, respectivamente. Foram calculados sensibilidade, espe-
cificidade, valores preditivos positivos e negativos, utilizando-se a tomografia computadorizada sem contraste intravenoso
como padrão de referência. Resultados: O método simplificado de cálculo para o diagnóstico de esteatose hepática na
fase portal mostrou sensibilidade de 100%, especificidade de 36%, valor preditivo negativo de 100% e valor preditivo
positivo de 75,8%. A taxa de falso-positivos foi 64%. Não foram encontrados falso-negativos. Conclusão: A utilização
da fase portal apresenta elevada sensibilidade para o diagnóstico de esteatose hepática, quando comparada à fase
sem contraste da tomografia computadorizada de abdome. Por outro lado, o método apresenta baixa especificidade.
Unitermos: Fígado gorduroso; Esteatose hepática; Hepatopatias; Tomografia; Tomografia computadorizada multidetec-
tores; Meios de contraste.
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where the disease is not associated with
alcohol consumption (in this case known as
nonalcoholic steatohepatitis – NASH), and
to cirrhosis(1). Data from the United States
of America estimates that 40 million adults
are affected by NASH(1). Other studies in-
dicate that the prevalence of HS in the gen-
eral population may reach 24%(2,3).
In cases where NASH is early diag-
nosed, the treatment may avoid progression
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INTRODUCTION
Hepatic steatosis (HS) has been consid-
ered a clinically significant condition due
the increased risk for progression to necro-
inflammatory alterations, even in cases
http://dx.doi.org/10.1590/S0100-39842013000300005
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to a final and irreversible stage of hepatic
cirrhosis(4). Additionally, HS patients may
be disqualified as eligible living liver do-
nor candidates for hepatic transplant be-
cause the steatotic liver is more vulnerable
to injuries from anesthetic procedures and
ischemic reperfusion(5–7). In this context, up
to 30% of living liver donor candidates are
rejected for presenting hepatic steatosis(8).
Percutaneous liver biopsy has been the
reference standard for diagnosis and stag-
ing of HS(4), but it is an invasive method
with possible complications. On the other
hand, imaging methods such as ultrasonog-
raphy (US), computed tomography (CT)
and magnetic resonance imaging (MRI)
have been extensively utilized, not only for
the comprehensive assessment of abdomi-
nal disorders, but specifically in the diag-
nosis of HS(1,4,9). US, despite being widely
available and without contraindications,
relies on subjective and hardly reproducible
criteria which do not allow a reliable quan-
tification of steatosis(4). MRI is currently
considered as being the most effective
noninvasive method for the diagnosis of
HS(4), but it is still a highly expensive
method and is not widely available in our
country. CT, on its turn, has been the
method most widely utilized in the evalu-
ation of abdominal disorders and is an im-
portant tool in the diagnosis of HS(10,11).
Several factors have contributed to such a
wide utilization, among them the develop-
ment of multidetector CT apparatuses
(MDCT), allowing faster images acquisi-
tion, with greater comfort for the patient
and high diagnostic accuracy. However, the
harmful effects of ionizing radiation inher-
ent to the method have been a constant
source of preoccupation(12,13).
Among the several strategies for radia-
tion dose reduction in CT scans, a thorough
review of CT protocols has been recom-
mended with the purpose of avoiding un-
necessary scan phases(14). The contrast-en-
hanced portal phase performed between 60
and 80 seconds after intravenous contrast
injection is isolatedly considered as being
the most useful phase in the greatest major-
ity of indications for upper abdomen CT,
provided the reliability and diagnostic ac-
curacy of the method is assured(9,14,15), lead-
ing to a tendency to abolish the non-con-
trast-enhanced phase. On the other hand,
according to several authors, the CT crite-
ria for diagnosis of HS are dependent on
such phase(10,11,16). Such a fact has stimu-
lated the undertaking of studies which at-
tempted to establish the value of the portal
phase isolatedly in the diagnosis of hepatic
steatosis(9,10,17). The most recent of those
studies demonstrated that, with the isolated
utilization of the portal phase, it is possible
to obtain accuracy similar to that obtained
with the criteria adopted at non-contrast-
enhanced CT in the diagnosis and quanti-
fication of HS(9). The authors proposed a
mathematical equation which takes into
consideration the average density of the
portal vein and the aorta based on measure-
ments obtained at three different sites and
the average density of the liver obtained
from eight measurements (two for each one
of the four segments of the right lobe). Such
a strategy, in spite of having demonstrated
good results, is time consuming for the in-
vestigator, making the method somewhat
tiresome and certainly more complex than
the simple measurements obtained with the
non-contrast-enhanced phase. Additionally,
the several variables involved in the pro-
cess, such as concentration, contrast me-
dium injection velocity and acquisition
time may influence the results(16), lead to
the necessity of validating the previous re-
sults and prove the usefulness of a simpli-
fied method for HS diagnosis by means of
contrast-enhanced CT.
Considering the prevalence of HS, the
present study was aimed to evaluate the
diagnostic capability of the portal phase
with a simplified calculation method, as
compared with the non-contrast-enhanced
phase of abdominal CT.
MATERIALS AND METHODS
The present study was approved by the
Committee for Ethics in Research of the
authors’ institution, and the application of
a term of free and informed consent was
waived.
The abdominal CT images were retro-
spectively analyzed regardless of clinical
indication, in the period between May,
2011 and February, 2012, until the arbi-
trarily established number of 100 HS pa-
tients, called “cases”, and 50 HS-free pa-
tients, called “controls”, was reached, uti-
lizing non-contrast-enhanced CT as a ref-
erence imaging method.
In the group of cases in the sample, 49
patients were men (mean age = 51.6 years
± 14.3) and 51 were women (mean age =
54.7 years ± 14.0). Among the “controls”
26 patients were men (mean age = 57.6
years ± 18.2) and 24 were women (mean
age = 53.2 years ± 18.4).
Only patients above the age of 18 and
with spontaneous requests for contrast-en-
hanced abdominal CT were included in the
present study. Exclusion criteria were the
following: a) heterogeneous liver; b) pa-
tients with innumerable lesions in both
liver lobes; c) inappropriate contrast me-
dium injection (for example: contrast me-
dium extravasation); d) images with arti-
facts (for example: respiratory artifacts)
which would make density measurements
inaccurate or unreliable; e) incomplete
images. Non-inclusion criteria were the
following: a) patients under the age of 18;
b) indication for non-contrast-enhanced
abdominal CT; c) patients with contraindi-
cation for iodinated contrast medium; d)
splenectomized patients.
The scans were performed in a Bril-
liance 64® model CT apparatus (Philips
Medical Systems; Best, The Netherlands),
with volumetric acquisition before and 70
seconds after intravenous injection of the
hydrosoluble iodinated contrast medium,
by means of an automatic injection pump
at a rate of 3–4 ml/s and 1.5–2 ml/kg of
body weight, with a maximum volume of
150 ml. The technical parameters com-
monly utilized at CT scans were the follow-
ing: a) collimation of 64 × 0.625 mm; b)
gantry rotation time = 0.5 s; c) reconstruc-
tion with 1 and 3 mm slice thickness; d)
pitch = 0.891; e) 120 kVp; f) mAs depend-
ing upon automatic modulation of the ra-
diation dose (DoseRight ACS®).
All the images were interpreted by a
single observer with three-year experience
in imaging diagnosis, on a Synapse® PACS/
3D (FujiFilm; USA) workstation. At the
moment of the interpretation, none of the
clinical data were available to the observer.
The differentiation between the two pa-
tient groups was based on the diagnostic
criteria for HS established for non-contrast-
enhanced CT, utilizing the analysis of he-
patic and splenic attenuation values in
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Hounsfield units (HU), considering that a
liver attenuation value lower than the
splenic attenuation value indicates the di-
agnosis of steatosis(4,17,18).
The diagnosis of HS with contrast-en-
hanced CT was obtained by means of the
method proposed by Kim et al.(9), utilizing
the formula [L – 0.3 × (0.75 × P + 0.25 ×
A)] / 0.7, where L corresponds to hepatic
attenuation, P corresponds to portal vein
attenuation, and A corresponds to abdomi-
nal aorta attenuation. The measurements
were performed in the portal venous con-
trast phase, i.e., between 60 and 80 seconds
after the initiation of the intravenous con-
trast medium injection.
In the original study, the variables L, P
and A were obtained from the averages of
eight measurements of the liver, three of the
portal vein and three of the aorta, respec-
tively, which makes the process quite bur-
densome and hardly practical.
Some studies have proposed that the uti-
lization of a single liver attenuation mea-
surement does not present significant dif-
ference in relation to the average obtained
after multiple measurements(11,19).
With such premise in mind and with the
objective of validating a simplified method
for the diagnosis of HS relying on the por-
tal phase isolatedly, a pilot study was ini-
tially undertaken with five patients without
HS (liver attenuation value higher than
splenic attenuation value in the non-con-
trast-enhanced phase), five with mild HS
(difference between liver and spleen at-
tenuation values > –10 HU), and five with
severe HS (difference between liver and
spleen attenuation values < –10 HU)(4),
comparing the values resulting from the
utilization of the above mentioned formula
with all mean values of the variables (origi-
nal method) with a single measurement for
each variable (simplified method). The
analysis of the pilot study was performed
by two independent investigators blinded
with respect to the results from the non-
contrast-enhanced phase. A almostperfect
agreement was observed between the origi-
nal and the simplified methods of calcula-
tion (kappa = 0.842; p = 0.001).
The initial results justified the continu-
ity of the present study, applying the pre-
viously proposed formula(9) with a single
measurement for each anatomical site
(right hepatic lobe, portal vein and aorta),
thus simplifying the method (Figure 1).
Kim et al.(9) have originally proposed
that results from their formula < 104 HU
are associated with steatosis grades > 5%.
Therefore, in the present study, the cutoff
point of < 104 HU was utilized as a diag-
nostic criterion for HS at the portal phase,
indicating steatosis greater than 5%(20–23).
Liver density values were obtained by
means of measurements of the liver attenu-
ation on circular regions of interest (ROI)
with 1.5 cm2(9) located in the right hepatic
lobe(4), avoiding vessels and eventual focal
lesions, both for the calculations in the non-
contrast-enhanced phase and in the portal
phase. The splenic attenuation was calcu-
lated in a similar manner. The measure-
ments of attenuation in the portal vein and
aorta were obtained at the level of the ce-
liac trunk, utilizing the ROIs which occu-
pied the largest possible area of the vascu-
lar lumen.
The L, P and A attenuation values ob-
tained in the analysis were entered into an
Excel® worksheet prepared for the auto-
matic calculation with the formula.
For the purpose of statistical analysis,
the patients were categorized as “with ste-
atosis” and “without steatosis”, both for the
non-contrast-enhanced phase and the por-
tal phase; and sensitivity, specificity, posi-
tive and negative predictive values as well
as the false-positive and false-negative
rates were calculated, considering the
evaluation obtained at non-contrast-en-
hanced CT as a reference standard.
RESULTS
By applying the proposed method for
the portal phase, from the 150 analyzed pa-
tients, 132 obtained results < 104 HU,
meeting the criteria for HS, and 18 obtained
results > 104 HU, being thus considered as
negative for HS.
The calculation of the portal phase ac-
curacy with the proposed simplified method
utilizing the non-contrast-enhanced phase
as a reference standard provided the follow-
ing results: 100% sensitivity; 36% specific-
ity, 100% negative predictive value; and
75.8% positive predictive value. The false
positive rate was 64%. No false negative
result was observed.
DISCUSSION
Several studies have been undertaken by
Brazilian authors approaching the impor-
tance of imaging methods in the evaluation
of liver diseases(24–28), with CT diagnosis of
HS being traditionally made according the
criteria applied to the non-contrast-en-
hanced phase(10,11,16). However, in a sce-
nario of increased preoccupation with the
harmful effects of ionizing radiation, and
considering the opportunity to obtain the
diagnosis of HS by means of the portal
contrast-enhanced phase and the fact that
such phase is the most useful in most ab-
dominal CT indications(9,14,15), the possibil-
ity of confirming the value of contrast-en-
hanced CT in the screening for HS becomes
particularly interesting.
In an attempt to establish a criterion for
diagnosis of HS by means of contrast-en-
hanced CT, Kim et al.(9) have proposed a
mathematical equation considering the
liver density in the portal vein and in the
aorta. Such form of calculation tends to be
less dependent in relation to potentially
limiting factors, such as differences in in-
jection velocity, amount, concentration or
type of contrast medium, problems pre-
sented by previous studies with the same
purposes(10,15,16).
As regards the previously utilized at-
tenuation measurements(9), the authors of
the present study proposed the utilization
of a single measurement for each variable,
thus simplifying the method and providing
results similar to those obtained by the
original authors. As the data regarding at-
tenuation values in the liver, aorta and por-
tal vein were entered into the Excel®
worksheet, the results could be obtained in
a pre-programmed and automatic manner;
and such method is already being utilized
by the residents in the authors’ institution
with good acceptance and results.
New methods for analysis of the portal
phase in the evaluation of HS are currently
being studied, for example, the definition
of areas with anomalous enhancement in
the gallbladder fossa or in the peripheral
zone of the hepatic segment IV, with 100%
specificity in the diagnosis of HS(29). By
combining such method with that proposed
in the present study, its specificity would be
incremented, increasing the value of the
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portal phase in the diagnosis of HS. Such
combination of diagnostic criteria may be
evaluated in future studies.
The present study has a number of limi-
tations. Because of its retrospective nature,
it was not possible to assure that all the CT
scans have rigorously followed the defined
protocol and the calibration of the device
for survey of the attenuation measurements.
Additionally, the proportion of patients
with HS was above the prevalence in the
general population, and such a fact might
have increased the positive predictive value
of the method. The adopted reference stan-
dard for calculation of accuracy was not
Figure 1. Measurements of attenuation required for the calculation according to the method originally proposed by Kim et al.(9) (A–D) and according to the
simplified method proposed by the present study (E).
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liver biopsy, but non-contrast-enhanced
CT, a method known to be less effective
than the histological analysis(4). On the
other hand, several studies have adopted a
similar method(9,10,15–17) and the present
study was not aimed at proposing a method
of choice for non-invasive diagnosis of HS,
but demonstrate that, with the portal phase,
it is possible to identify patients with HS,
without incurring in false negative results,
which would allow avoiding the utilization
of non-contrast-enhanced abdominal CT in
routine investigations. However, for those
patients under specific HS investigation,
and with the purpose of quantifying the
disease, the authors of the present study,
like others, understand that MRI is the most
effective method(4).
With the obtained results, it is possible
to conclude that abdominal CT in the por-
tal phase provides useful data as a screen-
ing method for HS, as compared with the
non-contrast-enhanced phase without con-
trast, being capable or ruling out the diag-
nosis of the disease with high sensitivity
and high negative predictive value. On the
other hand, the same assertion is not valid
as regards the confirmation of the diagno-
sis of HS because of the low specificity of
the method, with high rate of false-positive
results. It is possible that the combination
of criteria adopted with basis on the evalu-
ation of the portal phase increases the speci-
ficity and accuracy of the method in the
diagnosis of HS.
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